The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy

Agoston Gyula Szabo; Jonathan Thorsen; Katrine Fladeland Iversen; Mette Bøegh Levring; Birgitte Preiss; Carsten Helleberg; Marie Fredslund Breinholt; Emil Hermansen; Lise Mette Rahbek Gjerdrum; Søren Thorgaard Bønløkke; Katrine Nielsen; Eigil Kjeldsen; Elena Manuela Teodorescu; Marveh Dokhi; Eva Kurt; Casper Nørgaard Strandholdt; Mette Klarskov Andersen; Annette Juul Vangsted

doi:10.1002/ajh.26449

The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy

Agoston Gyula Szabo^*, Jonathan Thorsen, Katrine Fladeland Iversen, Mette Bøegh Levring, Birgitte Preiss, Carsten Helleberg, Marie Fredslund Breinholt, Emil Hermansen, Lise Mette Rahbek Gjerdrum, Søren Thorgaard Bønløkke, Katrine Nielsen, Eigil Kjeldsen, Elena Manuela Teodorescu, Marveh Dokhi, Eva Kurt, Casper Nørgaard Strandholdt, Mette Klarskov Andersen, Annette Juul Vangsted

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

2 Citations (Scopus)

Original language	English
Journal	American Journal of Hematology
Volume	97
Issue number	3
Pages (from-to)	E117-E120
ISSN	0361-8609
DOIs	https://doi.org/10.1002/ajh.26449
Publication status	Published - 2022

Access to Document

10.1002/ajh.26449

Cite this

Szabo, A. G., Thorsen, J., Iversen, K. F., Levring, M. B., Preiss, B., Helleberg, C., Breinholt, M. F., Hermansen, E., Gjerdrum, L. M. R., Bønløkke, S. T., Nielsen, K., Kjeldsen, E., Teodorescu, E. M., Dokhi, M., Kurt, E., Strandholdt, C. N., Andersen, M. K., & Vangsted, A. J. (2022). The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy. American Journal of Hematology, 97(3), E117-E120. https://doi.org/10.1002/ajh.26449

The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy. / Szabo, Agoston Gyula; Thorsen, Jonathan; Iversen, Katrine Fladeland; Levring, Mette Bøegh; Preiss, Birgitte; Helleberg, Carsten; Breinholt, Marie Fredslund; Hermansen, Emil; Gjerdrum, Lise Mette Rahbek; Bønløkke, Søren Thorgaard; Nielsen, Katrine; Kjeldsen, Eigil; Teodorescu, Elena Manuela; Dokhi, Marveh; Kurt, Eva; Strandholdt, Casper Nørgaard; Andersen, Mette Klarskov; Vangsted, Annette Juul.

In: American Journal of Hematology, Vol. 97, No. 3, 2022, p. E117-E120.

Research output: Contribution to journal › Letter › peer-review

Szabo, AG, Thorsen, J, Iversen, KF, Levring, MB, Preiss, B, Helleberg, C, Breinholt, MF, Hermansen, E, Gjerdrum, LMR, Bønløkke, ST, Nielsen, K, Kjeldsen, E, Teodorescu, EM, Dokhi, M, Kurt, E, Strandholdt, CN, Andersen, MK & Vangsted, AJ 2022, 'The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy', American Journal of Hematology, vol. 97, no. 3, pp. E117-E120. https://doi.org/10.1002/ajh.26449

Szabo, Agoston Gyula ; Thorsen, Jonathan ; Iversen, Katrine Fladeland ; Levring, Mette Bøegh ; Preiss, Birgitte ; Helleberg, Carsten ; Breinholt, Marie Fredslund ; Hermansen, Emil ; Gjerdrum, Lise Mette Rahbek ; Bønløkke, Søren Thorgaard ; Nielsen, Katrine ; Kjeldsen, Eigil ; Teodorescu, Elena Manuela ; Dokhi, Marveh ; Kurt, Eva ; Strandholdt, Casper Nørgaard ; Andersen, Mette Klarskov ; Vangsted, Annette Juul. / The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy. In: American Journal of Hematology. 2022 ; Vol. 97, No. 3. pp. E117-E120.

@article{735582fc2fe848dc9c5b0e43123adbc7,

title = "The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy",

author = "Szabo, {Agoston Gyula} and Jonathan Thorsen and Iversen, {Katrine Fladeland} and Levring, {Mette B{\o}egh} and Birgitte Preiss and Carsten Helleberg and Breinholt, {Marie Fredslund} and Emil Hermansen and Gjerdrum, {Lise Mette Rahbek} and B{\o}nl{\o}kke, {S{\o}ren Thorgaard} and Katrine Nielsen and Eigil Kjeldsen and Teodorescu, {Elena Manuela} and Marveh Dokhi and Eva Kurt and Strandholdt, {Casper N{\o}rgaard} and Andersen, {Mette Klarskov} and Vangsted, {Annette Juul}",

note = "Funding Information: We thank the Department of Internal Medicine and the Hematological Clinical Research Unit at Vejle Hospital for providing the financial and logistical background for this study. Data management for this study was provided by Open Patient Exploratory Network, University of Southern Denmark. Funding Information: We thank the Department of Internal Medicine and the Hematological Clinical Research Unit at Vejle Hospital for providing the financial and logistical background for this study. Data management for this study was provided by Open Patient Exploratory Network, University of Southern Denmark.",

year = "2022",

doi = "10.1002/ajh.26449",

language = "English",

volume = "97",

pages = "E117--E120",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "JohnWiley & Sons, Inc.",

number = "3",

}

TY - JOUR

T1 - The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy

AU - Szabo, Agoston Gyula

AU - Thorsen, Jonathan

AU - Iversen, Katrine Fladeland

AU - Levring, Mette Bøegh

AU - Preiss, Birgitte

AU - Helleberg, Carsten

AU - Breinholt, Marie Fredslund

AU - Hermansen, Emil

AU - Gjerdrum, Lise Mette Rahbek

AU - Bønløkke, Søren Thorgaard

AU - Nielsen, Katrine

AU - Kjeldsen, Eigil

AU - Teodorescu, Elena Manuela

AU - Dokhi, Marveh

AU - Kurt, Eva

AU - Strandholdt, Casper Nørgaard

AU - Andersen, Mette Klarskov

AU - Vangsted, Annette Juul

N1 - Funding Information: We thank the Department of Internal Medicine and the Hematological Clinical Research Unit at Vejle Hospital for providing the financial and logistical background for this study. Data management for this study was provided by Open Patient Exploratory Network, University of Southern Denmark. Funding Information: We thank the Department of Internal Medicine and the Hematological Clinical Research Unit at Vejle Hospital for providing the financial and logistical background for this study. Data management for this study was provided by Open Patient Exploratory Network, University of Southern Denmark.

PY - 2022

Y1 - 2022

U2 - 10.1002/ajh.26449

DO - 10.1002/ajh.26449

M3 - Letter

C2 - 34967035

AN - SCOPUS:85122077675

VL - 97

SP - E117-E120

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -